ATE241808T1 - Verwendungen von apoptin - Google Patents

Verwendungen von apoptin

Info

Publication number
ATE241808T1
ATE241808T1 AT96916378T AT96916378T ATE241808T1 AT E241808 T1 ATE241808 T1 AT E241808T1 AT 96916378 T AT96916378 T AT 96916378T AT 96916378 T AT96916378 T AT 96916378T AT E241808 T1 ATE241808 T1 AT E241808T1
Authority
AT
Austria
Prior art keywords
apoptin
apoptosis
normal cells
tumor
cells
Prior art date
Application number
AT96916378T
Other languages
English (en)
Inventor
Matheus Hubertus Mari Noteborn
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/484,939 external-priority patent/US6319693B1/en
Application filed by Leadd Bv filed Critical Leadd Bv
Application granted granted Critical
Publication of ATE241808T1 publication Critical patent/ATE241808T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Light Receiving Elements (AREA)
AT96916378T 1995-06-07 1996-06-07 Verwendungen von apoptin ATE241808T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/484,939 US6319693B1 (en) 1990-09-12 1995-06-07 Cloning of chicken anemia virus DNA
PCT/NL1996/000229 WO1996041191A1 (en) 1995-06-07 1996-06-07 Methods and uses for apoptin

Publications (1)

Publication Number Publication Date
ATE241808T1 true ATE241808T1 (de) 2003-06-15

Family

ID=23926260

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96916378T ATE241808T1 (de) 1995-06-07 1996-06-07 Verwendungen von apoptin

Country Status (11)

Country Link
EP (1) EP0830604B1 (de)
JP (1) JPH11506340A (de)
AT (1) ATE241808T1 (de)
AU (1) AU718422B2 (de)
CA (1) CA2221495C (de)
DE (1) DE69628431T2 (de)
DK (1) DK0830604T3 (de)
ES (1) ES2200065T3 (de)
NZ (1) NZ309171A (de)
PT (1) PT830604E (de)
WO (1) WO1996041191A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188832A1 (de) * 2000-09-08 2002-03-20 Leadd B.V. Verfahren zur Ablieferung der Tumor-spezifischen Apoptosis-auslösenden Aktivität von Apoptin
WO1999008108A1 (en) * 1997-08-12 1999-02-18 Leadd B.V. Determining the transforming capability of agents
AU2004233486B2 (en) * 1999-01-11 2007-09-13 Leadd B.V. Use of apoptosis inducing agents in the treatment of (auto)immune diseases
AU3083500A (en) * 1999-01-11 2000-08-01 Leadd B.V. Use of apoptosis inducing agents in the treatment of (auto)immune diseases
HUP0202688A2 (en) * 1999-09-02 2002-12-28 Leadd Bv Apoptin-associating protein
AU784723B2 (en) 1999-12-10 2006-06-01 Leadd B.V. Apoptin-associating protein
EP1186665A1 (de) * 2000-09-08 2002-03-13 Leadd B.V. Verfahren zur Ablieferung der Tumor-spezifischen Apoptosis-auslösenden Aktivität von Apoptin
WO2002020809A1 (en) * 2000-09-08 2002-03-14 Leadd B.V. A delivery method for the tumor specific apoptosis inducing activity of apoptin
EP1199363A1 (de) * 2000-10-20 2002-04-24 Leadd B.V. Phosphorylationsmodifikationen von Apoptin
EP1377667B1 (de) * 2001-03-30 2008-11-19 Leadd B.V. Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
AU2002259005A1 (en) * 2001-04-24 2002-11-05 Washington University Compositions and methods for inducing cancer cell death
AU2003214721A1 (en) * 2002-04-19 2003-11-03 Leadd B.V. Fragments of apoptin
AU2003228132A1 (en) * 2002-04-19 2003-11-03 Leadd B.V. Aberrant-specific pathways
EP2643343A1 (de) 2010-11-26 2013-10-02 Institut Pasteur Identifizierung eines menschlichen gyrovirus und anwendungen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9301272A (nl) * 1993-07-20 1995-02-16 Aesculaap Bv Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus.
US5981502A (en) * 1990-09-12 1999-11-09 Leadd B.V. Methods and compositions for inducing apoptosis in tumor cells

Also Published As

Publication number Publication date
AU718422B2 (en) 2000-04-13
CA2221495C (en) 2010-06-01
EP0830604A1 (de) 1998-03-25
DK0830604T3 (da) 2003-09-29
DE69628431D1 (de) 2003-07-03
PT830604E (pt) 2003-10-31
NZ309171A (en) 2000-04-28
ES2200065T3 (es) 2004-03-01
AU5913696A (en) 1996-12-30
EP0830604B1 (de) 2003-05-28
JPH11506340A (ja) 1999-06-08
DE69628431T2 (de) 2004-05-06
WO1996041191A1 (en) 1996-12-19
CA2221495A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
DE69628431D1 (de) Verwendungen von apoptin
Szumiel Ionizing radiation-induced cell death
Naito et al. TRAF6-deficient mice display hypohidrotic ectodermal dysplasia
DE69233399D1 (de) Menschliches cyclin e
DE69231245D1 (de) Veraendertes gen bei menschlichem colorektalem-krebs
ATE359515T1 (de) Proteinmarker für lungenkrebs und deren verwendung
Shin et al. Mechanism of the antitumor and radiosensitizing effects of a manganese porphyrin, MnHex-2-PyP
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
EP1004022A4 (de) Methoden und zusammensetzungen zum überwinden der resistenz gegen bio- und chemotherapie
Whiteman et al. Melanoma and sun exposure: where are we now?
WO2003016499A3 (en) Combinatorial methods for inducing cancer cell death
MX9706107A (es) Moldes para paneles prefabricados de hormigon.
MXPA02008239A (es) Gen humano de la esquizofrenia.
DE69637391D1 (de) Modifizierte myelin proteinmoleküle
ATE350662T1 (de) Markerproteine für prostatakrebs
WO2000018961A3 (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
DE69841322D1 (de) Hepatitis c rezeptorprotein cd81
Guthrie Dynamic compartmentalization of DNA repair proteins within spiral ganglion neurons in response to noise stress
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
MX9709860A (es) Metodos y usos para la apoptina.
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
TR199902866T2 (xx) Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler.
Kimeswenger Influence of Solar Waveband Interactions on Photocarcinogenesis
DE602004027387D1 (de) Prkcs als modifikatoren des beta catenin pfads und anwendungsverfahren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0830604

Country of ref document: EP

REN Ceased due to non-payment of the annual fee